July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Surgical and Nonsurgical Management and Outcomes of Submacular Hemorrhage Secondary to Neovascular Age-Related Macular Degeneration
Author Affiliations & Notes
  • Zubair Ansari
    Ophthalmology, University of Miami Bascom Palmer Eye Institute , Miami, Florida, United States
  • Harry W Flynn
    Ophthalmology, University of Miami Bascom Palmer Eye Institute , Miami, Florida, United States
  • Footnotes
    Commercial Relationships   Zubair Ansari, None; Harry Flynn, None
  • Footnotes
    Support  NIH Center Core Grant P30EY014801
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1453. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Zubair Ansari, Harry W Flynn; Surgical and Nonsurgical Management and Outcomes of Submacular Hemorrhage Secondary to Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1453.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Treatment of submacular hemorrhage secondary to neovascular age-related macular degeneration varies widely between practioners. With the advent of antiVEG-F agents, a new therapeutic modality was introduced as a viable alternative to previously used surgical interventions. There is little literature, however, on the reported outcomes of patients treated with those modalities. The pupose of this study is to report the visual outcomes of anti-VEGF monotherapy and antiVEGF therapy with surgery in the management of significant submacular hemorrhage secondary to wet AMD at the Bascom Palmer Eye Institute.

Methods : Retrospective cross sectional study evaluating patients presenting to the University of Miami, Bascom Palmer Eye Institute between January 1, 2009 and March 30, 2017 with a diagnosis of submacular hemorrhage secondary to neovascular age related macular degeneration
Main Outcome Measures include clinical features and Best Corrected Visual Acuity (BCVA) based on a standard Snellen chart.

Results : In patients who received ant-VEGF monotherapy treatments, the mean pre-submacular hemorrhage best corrected visual acuity (BCVA) was 20/100 (logMar 0.651 range 0 – 1.0) . The mean BCVA at presentation of submacular hemorrhage was CF (logMar 0.651 range 0.2 – 2.3), the mean BCVA at presentation at 3 months was 20/200 (logMar 1.0 range 0.1 – 1.2).). In patients who received anti-VEGF with subretinal tPA with retinotomy, the mean pre-submacular hemorrhage best corrected visual acuity (BCVA) was 20/90 (logMar 0.64 range 0.4 – 0.88) . The mean BCVA at presentation of a submacular hemorrhage was 20/400 (logMar 1.23 range 0.2 – 2.3), the mean BCVA at presentation at 3 months was 20/450 (logMar 1.0 range 0.3 – 2.3). There was no statistically significant difference in BCVA in patients who received antiVegF monotherapy and those who received antiVegF plus surgery at the 3 month time point.

Conclusions : There was a trend that anti-VEGF agents were shown to improve BCVA as monotherapy alone, though not statistically significant. There was no statistically significant difference in visual acuity between those eyes that had surgery plus anti-VEG-F therapy.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×